London, United Kingdom
London, United Kingdom

Time filter

Source Type

News Article | May 4, 2017
Site: www.prnewswire.com

Previously, Dr. Grines was vice president of academic and clinical affairs at Detroit Medical Center's Heart Hospital.  Before joining the Detroit hospital in 2011, Dr. Grines was vice chief of cardiovascular medicine at the Beaumont Hospital in Royal Oak, MI, where she spent two decades.  Dr. Grines led numerous multicenter clinical trials, including the PAMI trial that demonstrated primary PCI was superior to clot busting drugs and the Stent PAMI study, which confirmed the benefits of stents versus angioplasty for treating heart attacks. Research led by Dr. Grines revolutionized the management of heart attack patients across the world. "We are pleased to welcome Dr. Grines, one of the most esteemed interventional cardiologists in the country, as the chair of cardiology at the medical school," said Lawrence Smith, MD, Northwell Health's physician-in-chief and dean of the Hofstra Northwell School of Medicine.  "With exceptional clinical, teaching and research skills, Dr. Grines will develop a premiere cardiac research program as well as developing clinical trials that will give patients earlier access to the latest in diagnostics and therapeutics." Dr. Grines has had a significant impact on a number of areas of cardiology and interventional cardiology, but in particular with myocardial infarction, or heart attack.  She has a long history of research, publications and designing clinical trials. She has published more than 400 publications, numerous book chapters and hundreds of medical journal articles regarding cardiac catheterization, PCI, acute myocardial infarction, gene therapy and heart disease in women. She is the editor-in-chief of the Journal of Interventional Cardiology. Dr. Grines has been recognized as one of the "Best Doctors in America" and has received many regional and national awards.  In March, she received the American College of Cardiology's (ACC) Distinguished Mentor Award.  The Michigan ACC awarded Dr. Grines its Legacy Award, only the second person to receive the honor.  In 2016, she was presented with the Alumni Achievement Award for the Ohio State University College of Medicine, and received the Society for Cardiovascular Angiography and Interventions (SCAI) – Luminary in Interventional Cardiology award. Dr. Grines received her medical degree from Ohio State University in Columbus, OH and completed her internship and residency at the same university.  She completed her fellowship in cardiology from the University of Michigan Hospital in Ann Arbor, MI.  She is a member of numerous professional societies and is on the executive committee of the Society for Cardiovascular Angiography and Interventions, the scientific session program committee for the American College of Cardiology and is the chairperson for Women in Innovations. About Northwell Health Northwell Health is New York State's largest health care provider and private employer, with 21 hospitals and over 550 outpatient practices. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees – 15,000+ nurses and nearly 3,400 physicians, including nearly 2,700 members of Northwell Health Physician Partners -- are working to change health care for the better. We're making breakthroughs in medicine at the Feinstein Institute. We're training the next generation of medical professionals at the visionary Hofstra Northwell School of Medicine and the School of Graduate Nursing and Physician Assistant Studies. And we offer health insurance through CareConnect. For information on our more than 100 medical specialties, visit Northwell.edu. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/renowned-cardiologist-cindy-grines-md-joins-northwell-health-300451678.html


News Article | April 17, 2017
Site: www.prweb.com

Covington, Louisiana – Lakeview Regional Medical Center has added nearly 20 former Louisiana Heart Hospital physicians and providers to its Lakeview Regional Physician Group, helping provide continuity of care to patients affected by the heart hospital’s recent closure. The providers join more than a dozen experienced physicians and other staff at Lakeview Regional Physician Group, a multi-specialty practice offering family medicine, cardiology, orthopedics, general surgery and internal medicine. Most will continue in the same former Louisiana Heart Hospital clinic locations – in Covington, Hammond, Lacombe and Slidell – to minimize patient disruption. “We are honored that these highly skilled and experienced physicians and nurse practitioners chose to join our team at Lakeview Regional,” said Bret Kolman, Lakeview Regional president and CEO. “They bring with them an invaluable wealth of knowledge, years of experience and the same compassion we share with our patients.” Lakeview Regional Physician Group welcomes the following former LHH medical staff: Farhad Aduli, MD (Interventional Cardiology), Sergio Barrios, MD (Interventional Cardiology), John Breaux, MD (Cardiothoracic Surgery), Cary Gray, MD (General Surgery), Adam Hankins, MD (Vascular Surgery), Sandra Hubbard, NP (Nurse Practitioner), David Kaplan, MD (Vascular Surgery), Jeffery Kitch, APRN (Nurse Practitioner), Barry Kusnick, MD (Interventional Cardiology), Christina McKinley, MD (Family Medicine), Anthony Morales, MD (Interventional Cardiology), Adriana Nagy, MD (Noninterventional Cardiology), Carol Raymond, CFNP (Nurse Practitioner), Darren Rowan, MD (General Surgery), Richard Sanders, MD (Family Medicine), Jay Silverstein, MD (Noninterventional Cardiology), Ulrich Starke, MD (Internal Medicine), Danielle Tranchina, APRN (Nurse Practitioner), Bassam Wanna, MD (Cardiac Electrophysiology). “Patients can expect continuity of care with the highest quality in medical treatment,” Kolman said. “With five locations, patients will find the convenience a benefit, as well as a broader range of services and an increased network of physicians.” For more information, please visit LakeviewPhysicianGroup.com. The five locations, and physicians at each, include: 20 Starbush Circle, Covington, LA (985)871-6020 Frahad Aduli, MD Adraina Nagy, MD Christina Leal-McKinley, MD Ulrich Starke, MD Darren Rowan, MD Bassam Wanna, MD Jeffery Kitch, APRN Conveniently located on the North shore of Lake Pontchartrain just south of I-12 on 190, Lakeview Regional Medical Center (LRMC) is a 167-bed, private, acute care hospital that has been delivering award-winning, cost effective healthcare for over 35 years. Lakeview Regional’s Emergency Department offers 24-hour care by a comprehensive, multi-disciplinary team of board certified physicians. The hospital’s 750 highly trained employees are dedicated to providing the highest quality patient care through state of the art technology. The hospital is located on 53 lush acres at 95 Judge Tanner Blvd., Covington, Louisiana 70433. For more information about LRMC, please visit http://www.lakeviewregional.com or call (985) 867-3800.


News Article | February 15, 2017
Site: www.prweb.com

As American Heart Month kicks off, the Women’s Choice Award is challenging women across the U.S. to learn about the best hospitals in their communities for heart care. According to a recent study by Yale School of Medicine, where a patient goes for heart attack care may matter for both short and long-term risk of death. The Women’s Choice Award 2017 America’s Best Hospital’s for Heart Care uses an evidence-based methodology to select high-performing hospitals, including examination of 30-day survival rates, a measure Yale researchers found contributed to patients living an average of 9 to 14 months longer after a heart attack than those treated at low-performing hospitals. The study also found that high-performing hospitals keep patients who otherwise may have died healthier over the long term. “Heart disease is the leading killer of women,” said Delia Passi, founder and CEO of the Women’s Choice Award. “With such strong prevalence of heart disease, we want every woman to know where to find the very best heart care before she ever has an incident.” The methodology used to select America’s Best Hospitals for Heart Care is unique in that it evaluates: The Women’s Choice Award is encouraging women to learn which hospitals on the America’s Best list are “their heart hospitals” and to share the list with their circles of friends and loved ones through Facebook and other means during American Heart Month. “Women rely on other women for advice,” said Passi. “We’re encouraging women to share this potentially life-saving information as widely as possible.” The following hospitals have joined the Women’s Choice Award in empowering women and their families to make the best heart health choices: CHI St. Luke's Health Memorial, Lufkin, TX Comanche County Memorial Hospital, Lawton, OK Community Hospital, Munster, IN Florida Hospital North Pinellas, Tarpon Springs, FL Florida Hospital Zephyrhills, Zephyrhills, FL Harlingen Medical Center, Harlingen, TX Heart and Vascular Services at Hunterdon Medical Center, Flemington, NJ Heart Hospital of Lafayette, Lafayette, LA Hoffman Heart and Vascular Institute of Connecticut at Saint Francis Hospital and Medical Center, Hartford, CT Inter-Community Hospital, Covina, CA Jeffrey M. Carlton Heart & Vascular Institute at Hoag, Newport Beach, CA Norman Regional Health System, Norman, OK Parkview Medical Center, Pueblo, CO Queen of the Valley Hospital, West Covina, CA Riverside Medical Center, Kankakee, IL San Antonio Regional Hospital, Upland, CA Sharp Grossmont Hospital Heart & Vascular Center, La Mesa, CA Shasta Regional Medical Center, Redding, CA St. Catherine Hospital, East Chicago, IN St. Elizabeth Healthcare, Edgewood, KY St. Joseph’s Health, Syracuse, NY St. Luke's Hospital, Chesterfield, MO St. Mary Medical Center, Hobart, IN St. Peter’s Hospital, Albany, NY St. Tammany Parish Hospital, Covington, LA The Valley Hospital, Ridgewood, NJ Thomas Hospital, Fairhope, AL ABOUT THE WOMEN’S CHOICE AWARD® The Women’s Choice Award® is a trusted referral source, empowering women to make smart healthcare choices by identifying the country’s best healthcare institutions based on robust criteria that consider female patient satisfaction and clinical excellence. The Women’s Choice Award was recently honored by the INC 5000 List of America’s Fastest-Growing Private Companies in 2016 for a second consecutive year. Visit http://www.womenschoiceaward.com/ to learn more. The information contained in this release is not permitted to be used in a non-press related context without the express prior written consent of the Women’s Choice Award.


DETROIT, MI--(Marketwired - February 13, 2017) - SmithGroupJJR, one of the nation's leading architecture, engineering and planning firms, is pleased to announce that Tom Butcavage, Sam D'Amico, Mark Kranz and David Varner have been elevated to the American Institute of Architects (AIA) College of Fellows. The recognition reflects their significant contributions to architecture and society and achievement of a standard of excellence in the profession. The four from SmithGroupJJR will be among the 178 new Fellows recognized at an investiture ceremony at the AIA Conference on Architecture 2017, to be held April 27-29 in Orlando, Florida. Tom Butcavage, FAIA, LEED AP BD+C, is a SmithGroupJJR vice president and leader of the Higher Education Studio at the firm's Washington, DC office. He has spent the past 20 years as a pioneer in the programming, planning and design of award-winning and nationally significant higher education facilities across the U.S., ranging from instructional facilities and student centers to libraries and professional schools. Butcavage is widely recognized for his unparalleled expertise in law school design. He has led more than 20 law school projects, each containing a variety of spaces for specialized instruction, research and legal skills development. Among his most recently completed law schools are the University of Utah S.J. Quinney College of Law, American University Washington College of Law, George State University College of Law, and New York Law School - all which exemplify cutting-edge environments for modern legal education. Presently, he is leading the design of a number of new professional education facilities at the University of South Carolina, University of North Carolina at Chapel Hill, and Georgetown University. A frequent presenter at national academic conferences such as the Society for College and University Planning, American Bar Association and Association of College Unions International, Butcavage speaks on topics including the design of student spaces and maximizing student engagement through new facilities. He has served as a critic and lecturer at the Corcoran College of Art + Design and Catholic University of America School of Architecture and Planning. Butcavage is a graduate of Columbia University with a Master of Architecture, preceded by a BA in art history at Swarthmore College. His is a resident of Washington, DC's Shepherd Park neighborhood. Sam D'Amico, FAIA, LEED AP BD+C, is a SmithGroupJJR vice president and design leader for the firm's Health Practice. Based at its San Francisco office, he is now commencing his 35th year practicing architecture throughout the U.S. as well as parts of Asia. D'Amico approaches every project with a specific architectural response that integrates the client's culture, context and place. His design tenets include the integration of daylight, nature and art into the healthcare environment to improve the healing process. D'Amico has designed for world-class teaching institutions and national leaders in healthcare such as the University of California San Francisco Medical Center, Kaiser Permanente, and Barnes Jewish Hospital. Currently, D'Amico is design principal for a new medical office building and bed tower, part of a multi-year expansion program for Community Regional Medical Center in Fresno, California. His design of the new Robley Rex Veteran Administration Medical Center, a 1.2 million-square-foot replacement hospital to be constructed in Louisville, Kentucky, led to SmithGroupJJR's award of a prestigious AIA Academy of Architecture National Health Design Award, Unbuilt Category. Another D'Amico design, for the Fuwai Huazhong Cardiovascular and Heart Hospital, Zhenghou, Henan Province, China, was the recipient of an AIA San Francisco Citation Award for unbuilt design. At SmithGroupJJR, D'Amico is a member of the firm's National Design Committee. In 2016, he served as a featured panelist at firm's public forum on design, Perspectives, for a program titled, "The Fusion of Art and Architecture." A graduate from the University of Houston with a Bachelor of Architecture with Honors, the Houston, Texas native now resides in Lafayette, California, where he is on the Board of the city's Improvement Association. Mark Kranz, FAIA, LEED AP BD+C, vice president and design director at SmithGroupJJR, is known for his elegant and synthesized solutions for research and higher education environments across the U.S. As the designer of projects recognized by a total of 27 AIA design awards to-date, he believes that each has the potential for excellence, regardless of budget or constraints. Kranz, who is based at the firm's Phoenix office, is an advocate of pushing the boundaries of innovation and sustainability. He designed the LEED Platinum Energy Systems Integration Facility at the National Renewable Energy Lab in Golden, Colorado, leading a complex team and design vision for a high performance/ultra-low energy building later honored as R&D Magazine's "Lab of the Year." His design of the Defense POW/MIA Accounting Agency Center for Excellence, located at Joint Base Pearl Harbor Hickam, Oahu, Hawaii, was the recipient of the Naval Facilities Engineering Command (NAVFAC) 2015 Commander's Award for Design Excellence. Among Kranz's projects currently underway is the $82 million Engineering Building, now under construction at the University of Texas at Dallas. Scheduled for completion in 2018, the new, 208,000-square-foot building will house the university's rapidly growing mechanical engineering program. He is also serving design principal for the new $60 million San Diego County Crime Laboratory, slated to be completed in 2019. Kranz was elected to the SmithGroupJJR Board of Directors in 2015 and is a member of the firm's National Design Committee and Science & Technology Practice. He is a graduate of the University of Nebraska in Lincoln with a Bachelor of Science in architectural studies, followed by a Master of Architecture from Arizona State University. He now resides in Phoenix. David Varner, FAIA, LEED AP BD+C, is vice president and director of the firm's 200-person office in Washington, DC, located in the 1700 New York Avenue building in the heart of DC's monumental core. Varner is known for his talent in discovering and celebrating hidden environmental, economic and design opportunities in existing buildings. His special expertise and success in creating new value for owners, communities and cities through such building transformation is well demonstrated with the complete transformation of the 2.1 million-square-foot, Constitution Center, a repositioning of a 1960's property into the largest, privately-owned office building in Washington, DC. Certified LEED Gold, the building today is not only highly energy-efficient, but secure, elegant and fully leased. Varner is currently serving as SmithGroupJJR's principal-in-charge for one of the District's most exciting new buildings now under construction: the $60 million, 150,000-square-foot, DC Water Headquarters. When completed in late 2017 along the waterfront of the Anacostia River, the new building will set a new standard for low-energy, high-performance and resilient waterfront development. As a result of his expertise in existing buildings, transformation, planning and mixed-use development, Varner is frequently invited to join interdisciplinary panels of some of the nation's most significant leadership groups. In 2015 he was elected a Trustee of the Federal City Council, a position that catalyzes the collaboration of key business leaders in Washington, DC to solve challenging problems across the city. He is a long-time member of the Urban Land Institute and currently on its exclusive Redevelopment and Reuse Council. Varner has been a member of the SmithGroupJJR Board of Directors since 2011. He is graduate of Rice University with dual degrees: a Bachelor of Arts degree in architecture and art/art history and a Bachelor of Architecture. A native of Houston, Texas, Varner now lives in Arlington, Virginia. The American Institute of Architects Fellowship program was developed to elevate those architects who have made a significant contribution to architecture and society and who have achieved a standard of excellence in the profession. Election to fellowship not only recognizes the achievements of architects as individuals, but also their significant contribution to architecture and society on a national level. SmithGroupJJR (www.smithgroupjjr.com) is an integrated architecture, engineering and planning firm, employing more than 1,100 across 10 offices. In May 2016, SmithGroupJJR was ranked as one of the nation's top architecture firms by Architect magazine's Architect 50. A national leader in sustainable design, SmithGroupJJR has 420 LEED professionals and 160 LEED certified projects.


Efficacy of the suture based NobleStitch™ EL for Patent Foramen Ovale (PFO) WASHINGTON, DC--(Marketwired - November 14, 2016) - Dr. Michael Mullen (Consultant Cardiologist, St. Bartholomew's Heart Hospital, Chief Clinical Officer of HeartStitch) presented preliminary clinical data of PFO closure using the NobleStitch™ EL, in 112 patients, at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) Congress held in Washington, DC. http://content.onlinejacc.org/article.aspx?articleid=2576007 Attendees from around the world gathered in the Nation's Capital focusing on interventional cardiology therapies. Dr. Michael Mullen presented preliminary data on PFO closure with the suture based closure system NobleStitch EL in 3 separate sessions catching the attention of the structural heart interventionists. Dr. Mullen has extensive experience with the NobleStitch™ EL collaborating with NMT2 on the suture system's evolution. As a renowned Cardiologist and PFO expert, Dr. Mullen has been utilizing the NobleStitch™ EL for 8 years, most recently at St. Bartholomew's Hospital in London. The data presented from centres in the UK, Sweden, Germany, Italy, and Kazakhstan represented the multi-centre experience following commercial release of the NobleStitch EL system in Europe and Asia. In his presentations, to an audience of cardiologists and cardiac specialists from around the world, Dr. Mullen discussed that the NobleStitch™ EL is poised to be the device of choice for PFO closure. Dr. Mullen stated, "The NobleStitch is my first choice for PFO closure, it provides closure rates consistent with umbrella devices without the risks or long-term consequences of leaving leaving prosthetic devices in the heart. The Benefits of the NobleStitch over conventional PFO closure are slef evident. Their is minimal or no risk of complications including device migration, erosion, perforation, nickel allergy or atrial fibrillation. Additionally, the NobleStitch does not require any anti-coagulation, these collective benefits combined with the success we have demonstrated in the multi center data show that the NobleStitch technology is the new choice for PFO closure." Prof. Anthony Nobles, Chairman, CEO and Chief Clinical Specialist of Nobles Medical Technology commented, "With the renewed interest in PFO closure after the recent ruling of the FDA that PFO closure reduces recurrent stroke we have had a significant increase of interest in our NobleStitch Technology which has led to an increase in sales. The presentation of the multi center data now has given us the ability to show our products performance in a broad range of PFO's. This was the first time we presented our NobleStitch at the TCT, this is a major milestone for our company and we look forward to working with the many US based cardiologists that have approached us to provide the NobleStitch solution for their patients." The NobleStitch™ EL Suture System is a revolutionary technology in the treatment of structural heart disease of the atrial septum. The suture only system alleviates the need for any implanted device within the heart and therefore greatly reduces side effects associated with the traditional therapies. A PFO is a relatively common heart defect characterized by an unsealed tunnel between the right and left atria of the heart. This defect has been known to be present in anywhere between 27%-38% of people. However, in a number of cases, it is benign. The PFO is formed as a trace of the fetal circulation. When the chambers of a human heart begin to develop, a tunnel is made between the right and left atria, allowing blood to flow directly from the venous circulation to the arterial circulation, circumventing the non-functioning fetal lungs. Following birth, the pressure differential between the right and left atria changes with newly operational blood flow to the fully functioning lungs. Because of this, the tunnel eventually closes completely within the first few months. However, in some patients, the foramen ovale fails to seal and stays "patent". In patients with a Patent Foramen Ovale (PFO), the tunnel can reopen under elevated atrial pressure, such as coughing, or straining. A key issue with PFO is that it gives a pathway for blood clots to pass directly to the arterial circulation without being filtered out by the capillary bed of the lungs. A PFO can also let deoxygenated blood and certain chemicals cross over to the arterial side. The presence of a PFO has been linked to a number of clinical issues, mainly strokes, migraines and chronic fatigue. Developments are being made to solidify the link between PFO and strokes or migraines, and to identify patients that would benefit from PFO closure. An atrial septal defect (ASD) is a hole in the wall between the two upper chambers of your heart (atria). The condition is present from birth (congenital). Small atrial septal defects may close on their own during infancy or early childhood. Large and long-standing atrial septal defects can damage your heart and lungs. Small defects may never cause a problem and may be found incidentally. An adult who has had an undetected atrial septal defect for decades may have a shortened life span from heart failure or high blood pressure that affects the arteries in the lungs (pulmonary hypertension). Surgery may be necessary to repair atrial septal defects to prevent complications. Atrial septal aneurysm is a congenital cardiac abnormality that is characterized by saccular formation of the interatrial septum. Redundant atrial septal tissue results in bulging of the septum into either or both atria during the cardiac cycle. The diagnosis is best established with transesophageal echocardiography (TEE) since it can be easily missed with transthoracic echocardiography. Diagnostic criteria for ASA established by Hanley based on the appearance on echocardiography are: aneurysmal dilatation of the atrial septum protruding at least 1.5 cm beyond the plane of the atrial septum or phasic excursion of the interatrial septum during the cardiac cycle of at least 1.5 cm in total amplitude with a diameter at the base of the aneurysm of at least 1.5 cm. The condition can also be described using the Olivares-Reyes criteria, a classification based on the extent of excursion into each atrium. While the prevalence of ASA based on autopsy studies is <1%, the prevalence on TEE in non-selected patients is higher, in the range of 2% to 10%. Atrial septal aneurysm is clinically significant because of its association with cryptogenic stroke especially when there is a concurrent PFO. Approximately 70% of patients with ASA also have a PFO, while PFO is present in only 22% of patients without ASA. In one study, the combination of ASA and PFO was associated with a 33-fold higher risk of cryptogenic stroke. A meta-analysis has also found that ASA alone or ASA with PFO is associated with ischemic and cryptogenic strokes in patients <55 years of age. The strongest association is in those patients with both an ASA and a PFO. In patients <45 years of age with ischemic cerebral events, ASA should especially be suspected as a cardioembolic source. Mattioli and colleagues reported that 86% (43 of 50) of such patients had an ASA as the only possible etiology while 97% (42 of 43) of these younger patients with ASA also had a PFO. Patients with both ASA and PFO who have had a stroke are at substantial risk for recurrent stroke despite aspirin therapy. Mas and colleagues reported that the risk for recurrent stroke was 15% for patients with both PFO and ASA compared with 4.2% for patients with neither abnormality. These patients might benefit from more aggressive therapeutic strategies such as combination antiplatelet drugs, long-term anticoagulation or closure of the PFO. Nobles Medical Technology II, Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the PFO, ASD-closure, and vascular-suturing marketplace. The company does business under the name of Nobles Medical II (NMT II). Initial efforts of the company are focused on the innovative suture-based PFO closure system for closing the Patent Foramen Ovale (PFO), a tunnel between the right and left atria of the heart. The NobleStitch™ is approved for PFO Closure and Cardiovascular suturing in the European Union. The NobleStitch™ EL is FDA cleared for vascular suturing in the United States. NobleStitch™ EL is distributed worldwide by HeartStitch®, Inc. (HeartStitch® is a registered trademark of HeartStitch, Inc.). Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8197510, 8246636, 8348962, 8372089, 8469975, 8496676, 8709020, and 9131938. For more on Nobles Medical Technologies II visit www.NoblesMed2.com The following files are available for download:


News Article | February 21, 2017
Site: www.prweb.com

The Heart Institute of the Caribbean (HIC) has announced the opening of an ultra-modern, fully equipped cardiac intensive care unit (ICU) dedicated to the care of heart patients. The six bed high acuity unit at HIC, all private rooms, will be complemented with a 20 bed cardiac telemetry unit and will be the first and only such service in Jamaica dedicated to the care of heart patients. The intensive care and telemetry units at HIC have been designed to meet and exceed international standards with dedicated oxygen and medical air lines leading to individual bed head units for each patient. All beds are equipped with individual patient monitors linked to central monitoring stations and accessible to an international panel of experts to assist remotely in the care of patients to achieve optimal outcome. Furthermore, each bed in the Intensive Care Unit comes with a dedicated ventilator for those patients that may need ventilator support. Three zones of healing music are provided to create comfort for patients while being treated. “No effort was spared in ensuring that the units meet and in most cases exceed current international standards. That was the reason we engaged the services of one of the leading hospital architects in the world, Ansel & Bailey, based in London, UK with a track record of high quality healthcare design for over 100 years," said Dr. Ernest Madu, Founder and CEO of Heart Institute of the Caribbean. Dr. Madu further indicated, “We recognize that a very important factor in ensuring good outcome for critically ill patients is infection control. In recognition of this, we have employed the use of Air Handling Units and ensured that the intensive care unit has a laminar air flow environment, allowing for 20 to 25 air exchanges per hour, thus providing clean and filtered air at all times for patients and staff." Additionally, all internal walls of the ICU are covered with anti-bacterial panels further drastically reducing the risk of infection. Cardiac Intensive Care Units (CICU) have been in existence for more than 50 years and have been shown to significantly improve survival and outcome for patients with heart disease. Unfortunately, even though cardiovascular disease is the number 1 cause of death in Jamaica, there has not been a dedicated cardiac or coronary intensive care unit in Jamaica, until now. While there are several intensive care unit beds in a few hospitals in Jamaica, none of these are dedicated cardiac care units, which are usually specifically designed and equipped to cater to the specialized needs of heart patients. With the new cardiac ICU at HIC, heart disease patients in Jamaica now have the privilege of being cared for in a specialized cardiac intensive care unit specially designed and equipped for the care of heart patients. The Cardiac ICU at HIC will be staffed by outstanding Cardiologists, Critical Care Specialists and Cardiovascular Nurses & Techs with specialized training in critical care cardiology and is expected to offer the best local option for patients with proven or suspected heart attacks and other cardiac emergencies. The current development is consistent with HIC’s tradition of innovation and leadership in providing high quality, accessible and affordable cardiovascular care to patients in Jamaica and the wider Caribbean. This further cements the position of HIC as the only dedicated full service Heart Hospital in Jamaica. The units are expected to open to the public in March 2017. In line with our vision of providing high quality cardiac care that is accessible and affordable, HIC has put in place mechanisms to ensure that these services will be accessible to all patients including those with significant financial constraints. We have done so for years with other services including offering Free Angiograms to heart attack patients in public hospitals, building Heart Stations in communities and also hosting ECG Days that ensure services to the public at heavily subsidized rates – all supported by the work of the HIC Foundation. HIC has won multiple local and international awards for innovation and leadership in cardiovascular healthcare service delivery. http://www.caribbeanheart.com


News Article | October 31, 2016
Site: globenewswire.com

ALBUQUERQUE, N.M., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Lovelace Health System announced today that it has selected TriCore Reference Laboratories (TriCore) for inpatient and outpatient laboratory management services at its Albuquerque hospitals. The new agreement will begin February 21, 2017. "We are pleased to be contracting with a local, leading provider of reference laboratory services," said Ron Stern, CEO of Lovelace Health System.   While providing world-class laboratory services, TriCore is also a big part of the community in Albuquerque and New Mexico at large. Founded in 1988, TriCore is an independent laboratory headquartered in Albuquerque that provides over 1700 full-service, state-of-the-art laboratory tests to health care professionals and their patients with 98.5% of testing performed on site.   "We are honored to have been chosen by Lovelace Health System. Our common dedication to improving the way health care is delivered will enhance the lives of those in our community," said Khosrow Shotorbani, CEO TriCore Reference Laboratories. "Our commitment to this community keeps testing and jobs in New Mexico. It is a long-held belief of TriCore that laboratory testing should be done nearest to the patient as clinically appropriate and economically feasible for the best patient care. This contract allows Lovelace to maintain control over the core competency of this critical part of their ecosystem, while controlling cost and optimizing care, both now and in the future. TriCore is proud to be a part of this venture."   "Since our inception in 1998, TriCore has been providing accurate and timely laboratory results to all physicians and advanced practitioners in the region. This new agreement with Lovelace builds on our laboratory foundation as well as our new information technology platform to integrate results and improve patient care." said Dr. Crossey, CMO at TriCore.   Lovelace Health System consists of Lovelace Medical Center, Lovelace Rehabilitation Hospital, Lovelace Women's Hospital, Lovelace Westside Hospital, Heart Hospital of New Mexico at Lovelace Medical Center, Lovelace Regional Hospital-Roswell and Lovelace Medical Group. TriCore Reference Laboratories is an independent clinical reference laboratory that provides over 1,700 full-service, state-of-the-art laboratory tests to health care professionals and their patients. TriCore also provides investigational services including FDA-regulated clinical trials, IRB-approved studies, device and diagnostic instrument testing. TriCore serves global biotech firms as well as academic clients. For more information, visit tricore.org


AMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE:PHG, AEX:PHIA), a leader in health technology, today announced the global launch of Azurion, its next generation image-guided therapy platform, which forms the new core of its integrated solutions portfolio for the fast growing image-guided therapy market. As a leader in this market, Philips offers integrated solutions comprising interventional imaging technologies and planning and navigation software combined with interventional devices - including catheters for diagnosis and therapy - and a broad range of services, all aimed at helping clinicians to provide superior care at predictable costs. Following the acquisition of Volcano in 2015, via which Philips has become a leader in advanced catheters for diagnosis and therapy, the company is now further cementing its overall leadership in the EUR 5 billion image-guided therapy market with one of its largest global product launches in recent years. Philips’ Azurion image-guided therapy platform for interventional labs is the result of a multi-year development program conducted in close collaboration with leading clinicians in the field. This next generation platform features a state-of-the-art ergonomic design with an easy-to-use intuitive user interface, enabling clinicians to swiftly and confidently perform a wide range of routine and complex procedures in the interventional lab. With the rapid growth of image-guided therapy procedures, hospitals and health systems are increasingly faced with the need to control costs, while improving their standards of care. Azurion has been designed to address these challenges and is equipped with new workflow options and performance dashboards, as well as an upcoming range of productivity improvement services. The Azurion platform also features over 1,000 new components, including an enhanced flat-panel detector, and Philips’ newly developed ConnectOS operating system for the seamless integration of real-time information from all relevant technologies in the interventional lab. All of these components work together to deliver high image quality at ultra-low X-ray dose and real-time image processing on multiple work spots within the interventional lab. Parallel working enables the team of clinicians to complete different tasks simultaneously in the interventional lab, saving valuable time without compromising quality of care. Azurion features procedure cards that allow clinicians to pre-program routine tasks and user preferences, helping to minimize preparation errors and further reducing preparation and procedure time. Philips has pioneered a steady stream of innovations in planning and navigation software for areas such as vascular surgery (e.g. VesselNavigator), interventional cardiology (e.g. EchoNavigator), interventional oncology (e.g. EmboGuide), and interventional neuroradiology (e.g. AneurysmFlow). All these advanced interventional tools integrate seamlessly into the Azurion platform to support the clinical workflow. Driven by their benefits for patients and care providers, minimally-invasive therapies, such as the catheter-based treatment of certain tumors, aneurysms, obstructed blood vessels, heart rhythm disorders and defective heart valves, continue to grow fast. In addition to reduced patient trauma and shorter recovery times, such procedures also have the benefit of allowing the treatment of patients who would not be able to withstand the trauma of open surgery. However, during such procedures, clinicians cannot directly see and feel the organs they are working on. Effective imaging, measurement and navigation technologies are therefore key to guiding minimally-invasive procedures. At the heart of the interventional lab, these technologies allow identification and visualization of target organs and tissues, the operation of interventional devices, and the placement of implants, leading to improved chances of therapy success. “For over 30 years, we’ve pioneered minimally-invasive treatments that help our patients get back to their daily lives,” said Barry T. Katzen, MD, founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute, Baptist Health South Florida (U.S.). “The imaging environment is critical to perform such procedures efficiently and effectively. As an interventionalist, we want to be in the cockpit, similar to a pilot in an airplane, where we have control of everything we need and have all the relevant functions at our finger tips. Philips’ next generation image-guided therapy platform just takes it to a whole other level and allows interventionalists to accomplish the procedures quicker and more efficiently, which benefits the patient." “As a leader in image-guided therapy, we have been driving continuous innovation to address rising patient volumes and increased procedure complexity,” said Bert van Meurs, Business Leader Image Guided Therapy at Philips. “Hundreds of Philips developers, engineers and designers and dozens of our clinical partners across the world have collaborated to completely redesign the heart of our portfolio. With the launch of our new Azurion platform, which was designed to optimize system integration and lab performance, we can deliver new turnkey solutions that support our customers in maintaining high standards of quality and patient care at predictable costs.” “We are on an exciting journey to strengthen the Tampere Heart Hospital’s position as a Northern European center of excellence for cardiac care,” said Aki Haukilahti, Executive Vice President and CFO of Heart Hospital, Tampere University Hospital (Finland). “As part of our long-term strategic partnership with Philips, we have collaborated on a turnkey solution based on the new Azurion product family. With this solution, Philips provides us with advanced technologies and an excellent user experience, combined with services for guaranteed uptime, seamless integration into our hospital workflows, staff training and education, and enhancement of our productivity. This enables our staff to fully focus on what they do best – providing superior care to our patients.” Click on this link or type www.philips.com/azurion in your internet browser to visit the Philips Azurion website. Royal Philips (NYSE:PHG, AEX:PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the global launch of Azurion, its next generation image-guided therapy platform, which forms the new core of its integrated solutions portfolio for the fast growing image-guided therapy market. As a leader in this market, Philips offers integrated solutions comprising interventional imaging technologies and planning and navigation software combined with interventional devices - including catheters for diagnosis and therapy - and a broad range of services, all aimed at helping clinicians to provide superior care at predictable costs. Following the acquisition of Volcano in 2015, via which Philips has become a leader in advanced catheters for diagnosis and therapy, the company is now further cementing its overall leadership in the EUR 5 billion image-guided therapy market with one of its largest global product launches in recent years. Philips' Azurion image-guided therapy platform for interventional labs is the result of a multi-year development program conducted in close collaboration with leading clinicians in the field. This next generation platform features a state-of-the-art ergonomic design with an easy-to-use intuitive user interface, enabling clinicians to swiftly and confidently perform a wide range of routine and complex procedures in the interventional lab. With the rapid growth of image-guided therapy procedures, hospitals and health systems are increasingly faced with the need to control costs, while improving their standards of care. Azurion has been designed to address these challenges and is equipped with new workflow options and performance dashboards, as well as an upcoming range of productivity improvement services. Azurion is Philips' next generation image-guided therapy platform and the new core of its integrated solutions portfolio. Azurion supports a full range of configurations across a broad spectrum of image-guided therapy procedures. These include configurations for high volume routine procedures and flexible configurations for advanced procedures. Harnessing vital procedural information from various sources, such as imaging systems, interventional devices, navigation tools and patient health records, Azurion provides interventional staff members with the control and information they need to perform procedures efficiently. The Azurion platform also features over 1,000 new components, including an enhanced flat-panel detector, and Philips' newly developed ConnectOS operating system for the seamless integration of real-time information from all relevant technologies in the interventional lab. All of these components work together to deliver high image quality at ultra-low X-ray dose and real-time image processing on multiple work spots within the interventional lab. Parallel working enables the team of clinicians to complete different tasks simultaneously in the interventional lab, saving valuable time without compromising quality of care. Azurion features procedure cards that allow clinicians to pre-program routine tasks and user preferences, helping to minimize preparation errors and further reducing preparation and procedure time. Philips has pioneered a steady stream of innovations in planning and navigation software for areas such as vascular surgery (e.g. VesselNavigator), interventional cardiology (e.g. EchoNavigator), interventional oncology (e.g. EmboGuide), and interventional neuroradiology (e.g. AneurysmFlow). All these advanced interventional tools integrate seamlessly into the Azurion platform to support the clinical workflow. Driven by their benefits for patients and care providers, minimally-invasive therapies, such as the catheter-based treatment of certain tumors, aneurysms, obstructed blood vessels, heart rhythm disorders and defective heart valves, continue to grow fast. In addition to reduced patient trauma and shorter recovery times, such procedures also have the benefit of allowing the treatment of patients who would not be able to withstand the trauma of open surgery. However, during such procedures, clinicians cannot directly see and feel the organs they are working on. Effective imaging, measurement and navigation technologies are therefore key to guiding minimally-invasive procedures. At the heart of the interventional lab, these technologies allow identification and visualization of target organs and tissues, the operation of interventional devices, and the placement of implants, leading to improved chances of therapy success. "For over 30 years, we've pioneered minimally-invasive treatments that help our patients get back to their daily lives," said Barry T. Katzen, MD, founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute, Baptist Health South Florida (U.S.). "The imaging environment is critical to perform such procedures efficiently and effectively. As an interventionalist, we want to be in the cockpit, similar to a pilot in an airplane, where we have control of everything we need and have all the relevant functions at our finger tips. Philips' next generation image-guided therapy platform just takes it to a whole other level and allows interventionalists to accomplish the procedures quicker and more efficiently, which benefits the patient." "As a leader in image-guided therapy, we have been driving continuous innovation to address rising patient volumes and increased procedure complexity," said Bert van Meurs, Business Leader Image Guided Therapy at Philips. "Hundreds of Philips developers, engineers and designers and dozens of our clinical partners across the world have collaborated to completely redesign the heart of our portfolio. With the launch of our new Azurion platform, which was designed to optimize system integration and lab performance, we can deliver new turnkey solutions that support our customers in maintaining high standards of quality and patient care at predictable costs." "We are on an exciting journey to strengthen the Tampere Heart Hospital's position as a Northern European center of excellence for cardiac care," said Aki Haukilahti, Executive Vice President and CFO of Heart Hospital, Tampere University Hospital (Finland). "As part of our long-term strategic partnership with Philips, we have collaborated on a turnkey solution based on the new Azurion product family. With this solution, Philips provides us with advanced technologies and an excellent user experience, combined with services for guaranteed uptime, seamless integration into our hospital workflows, staff training and education, and enhancement of our productivity. This enables our staff to fully focus on what they do best - providing superior care to our patients." Click on this link or type http://www.philips.com/azurion in your internet browser to visit the Philips Azurion website. Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.

Loading Heart Hospital collaborators
Loading Heart Hospital collaborators